Optibrium and PostEra Collaborate to Integrate AI Drug Discovery Solutions

Optibrium and PostEra Collaborate to Integrate AI Drug Discovery Solutions

by John.norman | Mar 15, 2023 | News

​Optibrium and PostEra Collaborate to Integrate AI Drug Discovery Solutions The collaboration will connect PostEra’s synthesis prediction technology with Optibrium’s comprehensive platform for design, optimisation and data analysis for small molecule discovery...

Optibrium appoints Steve Yemm as Chief Commercial Officer

by Michelle Harrison | Jan 17, 2023 | News

Optibrium appoints Steve Yemm as Chief Commercial Officer    New role will lead global commercial strategy and development as Optibrium continues to scale its drug discovery technologies and team. Latest in a series of senior hires as the Company continues its...

Optibrium appoints Ian Smith as Chief Technology Officer

by John.norman | Nov 23, 2022 | News

Optibrium appoints Ian Smith as Chief Technology Officer   New role will lead technology development as the Company continues to scale team and global business operations. The appointment of former Merck, Sharp and Dohme (MSD) Director of R&D Analytics...

Optibrium and Lhasa Limited advance predictive modelling for drug-metabolising enzymes

by Michelle Harrison | Nov 2, 2022 | News

Optibrium and Lhasa Limited advance predictive modelling for drug-metabolising enzymes   Optibrium and Lhasa Limited publish joint peer-reviewed research in the Journal of Medicinal Chemistry, expanding predictive modelling beyond human Cytochrome P450. Study...

Optibrium expands operations in North America for AI and computational drug discovery technologies

by Michelle Harrison | Oct 18, 2022 | News

Optibrium expands operations in North America for AI and computational drug discovery technologies   Establishment of Optibrium Inc. bolsters ongoing strategic Company growth and strenghtens direct US customer support. Dr Tamsin Mansley promoted to President of...

J.Med.Chem publish; Predicting Regioselectivity of AO, CYP, FMO and UGT Metabolism Using Quantum Mechanical Simulations and Machine Learning

by John.norman | Oct 17, 2022 | News

J. Med. Chem, publish; Predicting Regioselectivity of AO, CYP, FMO and UGT Metabolism Using Quantum Mechanical Simulations and Machine Learning. Mario Öeren,† Peter J. Walton, †, ‡ James Suri, †, § David J. Ponting, ^ Peter A. Hunt, † Matthew D. Segall †   †...
« Older Entries

Recent Posts

  • Webinar: Integrated AI Synthesis Prediction in Drug Discovery
  • Optibrium and PostEra Collaborate to Integrate AI Drug Discovery Solutions
  • StarDrop 7.4 heat maps
  • StarDrop Open Training – March
  • Optibrium appoints Steve Yemm as Chief Commercial Officer

Archives

Categories

  • Cerella
  • Downloads
  • Drug Discovery Applications
  • Events
  • Example Code
  • General
  • In Silico Modelling
  • Latest Videos
  • Models
  • Multi-Parameter Optimisation
  • News
  • Ocura
  • Open Training
  • Pipeline Pilot Protocols
  • Presentations and Webinars
  • Publications and presentations
  • Scoring Profiles
  • Scripts/Addons
  • StarDrop Hints and Tips
  • StarDrop Modules and Features
  • StarDrop Tutorials
  • Tutorials
  • Upcoming webinar
  • Videos
  • Webinars

Meta

  • Register
  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

The Optibrium team works at the forefront of decision-analysis and predictive modelling research, developing innovative products that enhance the efficiency and productivity of drug discovery.

enquiries & support

General: [email protected]
StarDrop: [email protected]
Cerella: [email protected]
Press: [email protected]
Vacancies: [email protected]

  • Follow
  • Follow
further information

View our Privacy Policy

Copyright © 2023 Optibrium, Ltd. All Rights Reserved.
Optibrium™, StarDrop™, Inspyra™, Augmented Chemistry®, Cerella™, Ocura™, Glowing Molecule™, WhichP450™, Auto-Modeller™, Nova™, MPO Explorer™ and Card View® are trademarks of Optibrium Ltd. Matsy™ is a trademark of NextMove Software Ltd., BIOSTER™ is a trademark of iKem Szolgáltató és Kereskedelmi BT, Derek Nexus™ is a trademark of Lhasa Ltd., Surflex eSim3D™ is a trademark of BioPharmics LLC, and SeeSAR™ is a trademark of BioSolveIT GmbH. US Patent Numbers 9,224,098 and 9,367,812

Website designed and developed by Identity Creative.

Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}